Stockscreener 앱 받기
3.00
4.90%
0.14
시간 외 거래:
3.00
전일 마감가:
$2.86
열려 있는:
$2.8
하루 거래량:
250.10K
Relative Volume:
0.96
시가총액:
$73.94M
수익:
$23.26M
순이익/손실:
$-63.41M
주가수익비율:
-1.2295
EPS:
-2.44
순현금흐름:
$-64.56M
1주 성능:
+25.52%
1개월 성능:
+30.43%
6개월 성능:
+71.43%
1년 성능:
+52.28%
1일 변동 폭
$2.7519
$3.04
1주일 범위
$2.07
$3.60
52주 변동 폭
$1.21
$3.60
Aadi Bioscience Inc Stock (AADI) Company Profile
명칭
Aadi Bioscience Inc
전화
424-473-8055
주소
17383 SUNSET AVENUE, PACIFIC PALISADES
AADI을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AADI
Aadi Bioscience Inc
|
3.00 | 73.94M | 23.26M | -63.41M | -64.56M | -2.36 |
|
VRTX
Vertex Pharmaceuticals Inc
|
408.18 | 105.12B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
714.47 | 78.51B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
629.99 | 37.67B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
243.25 | 31.37B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
114.13 | 27.36B | 3.30B | -501.07M | 1.03B | -2.1146 |
Aadi Bioscience Inc Stock (AADI) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-08-27 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2024-08-21 | 다운그레이드 | Jefferies | Buy → Hold |
| 2024-08-21 | 다운그레이드 | TD Cowen | Buy → Hold |
| 2023-12-15 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2022-01-11 | 개시 | Jefferies | Buy |
| 2021-10-01 | 개시 | Cowen | Outperform |
| 2021-09-14 | 개시 | Ladenburg Thalmann | Buy |
| 2021-09-08 | 개시 | Piper Sandler | Overweight |
모두보기
Aadi Bioscience Inc 주식(AADI)의 최신 뉴스
Aadi Bioscience Enters Into Multiple Strategic Agreements, Including $100M Stock Purchase and License Agreement - Defense World
Aadi Bioscience Leads 3 Promising US Penny Stocks - Simply Wall St
Aadi Bioscience rockets 72% on key updates - MSN
Aadi Bioscience’s Strategic Agreements and Funding Moves - Yahoo Finance
Wilson Sonsini Advises Aadi Bioscience on $100 Million Sale of FYARRO®, $100 Million PIPE Financing and License Agreement for ADC Portfolio - Wilson Sonsini
Asia Deal Watch: Kaken Obtains Aadi Subsidiary And Cancer Drug Fyarro - Scrip
Why Is Cancer-Focused Aadi Bioscience Stock Trading Higher On Friday? - Benzinga
Aadi Bioscience stock soars on licensing and sale deals - Investing.com India
Aadi Bioscience, Inc. Appoints Baiteng Zhao to its Board of Directors - Marketscreener.com
Aadi Bioscience Transforms with In-Licensing of Novel ADC Portfolio, $100 Million Sale of FYARRO® and $100 Million PIPE Financing - Yahoo Finance
Kaken Pharmaceutical Co., Ltd. agreed to acquire Aadi Subsidiary, Inc. from Aadi Bioscience, Inc. for $100 million. - Marketscreener.com
Clinical Trials News Live Feed - StockTitan
Aadi Bioscience, Inc. (NASDAQ:AADI) Short Interest Update - MarketBeat
AADI Enlists NY Court To Enforce Cancer Drug Award - Law360
Aadi Bioscience, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Short Interest in Aadi Bioscience, Inc. (NASDAQ:AADI) Decreases By 8.8% - MarketBeat
GSA Capital Partners LLP Cuts Stake in Aadi Bioscience, Inc. (NASDAQ:AADI) - Defense World
Aadi Bioscience, Inc. (AADI) Reports Q3 Loss, Tops Revenue Estimates - MSN
US Penny Stocks Under $90M Market Cap To Watch - Simply Wall St
BML Capital Management LLC Takes $4.12 Million Position in Aadi Bioscience, Inc. (NASDAQ:AADI) - MarketBeat
Aadi Bioscience Reports Q3 2024 Earnings and Growth - TipRanks
Aadi Bioscience Faces Potential Financial Strain from Securities Class Action Risks - TipRanks
Aadi Bioscience earnings matched, revenue topped estimates By Investing.com - Investing.com Canada
Aadi Bioscience Q3 Sales Surge 21% YoY, FYARRO Growth Drives Strong Performance | AADI Stock News - StockTitan
Aadi Bioscience to Report Third Quarter 2024 Results and Corpora - GuruFocus.com
Aadi Bioscience to Report Third Quarter 2024 Results and Corporate Update - BioSpace
Aadi Bioscience to Report Fourth Quarter and Full-Year 2023 Resu - GuruFocus.com
Aadi plunges 36% as phase 2 trial for solid tumors asset unlikely to meet goal - MSN
Aadi Bioscience CEO sells shares worth $18,796 By Investing.com - Investing.com South Africa
Aadi Bioscience CEO sells shares worth $18,796 - Investing.com India
Wilson Sonsini Defeats $341 Million Arbitration Claim Against Aadi Bioscience - Wilson Sonsini
DADA’s 2023 Market Dance: Down -64.46% – Time to Invest? - The InvestChronicle
Pacer Advisors Inc. Sells 1,089 Shares of Analog Devices, Inc. (NASDAQ:ADI) - Defense World
A Glimpse Into The Expert Outlook On Analog Devices Through 8 Analysts - Benzinga
Nippon Life Global Investors Americas Inc. Makes New $1.10 Million Investment in Analog Devices, Inc. (NASDAQ:ADI) - Defense World
Market Highlights: Aditxt Inc (ADTX) Ends on a Low Note at 0.38 - The Dwinnex
Applied Dna Sciences Inc (APDN) presents a great opportunity, but the stock is slightly overvalued - US Post News
‘It felt like the world had ended’; Aadi Adeel on his father’s passing - TheCurrrent.pk
Analog Devices (NASDAQ:ADI) Downgraded to "Hold" at Truist Financial - MarketBeat
Magnetar Financial LLC Lowers Stake in ADMA Biologics, Inc. (NASDAQ:ADMA) - MarketBeat
Intech Investment Management LLC Trims Holdings in Analog Devices, Inc. (NASDAQ:ADI) - Defense World
There is no way Aditxt Inc (ADTX) can keep these numbers up - SETE News
AE Wealth Management LLC Has $4.39 Million Stock Holdings in Analog Devices, Inc. (NASDAQ:ADI) - Defense World
Edgestream Partners L.P. Acquires New Stake in Analog Devices, Inc. (NASDAQ:ADI) - Defense World
Healthcare stock jumps after it enters in an agreement to set up woman and children hospital - Trade Brains
Adairs Ltd Director Increases Share Holdings - TipRanks
Profund Advisors LLC Grows Position in Analog Devices, Inc. (NASDAQ:ADI) - Defense World
Quest Investment Management LLC Cuts Holdings in Analog Devices, Inc. (NASDAQ:ADI) - Defense World
Summit Trail Advisors LLC Buys 264 Shares of Analog Devices, Inc. (NASDAQ:ADI) - Defense World
Sei Investments Co. Increases Stock Position in Analog Devices, Inc. (NASDAQ:ADI) - Defense World
Applied DNA Regains Compliance with Nasdaq Minimum Bid Price Requirement - Chronicle-Tribune
Aadi Bioscience Inc (AADI) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.10%
0.76%
자본화:
|
볼륨(24시간):